Patent Issued for Compositions and methods for treating cancer using RHOA dominant negative forms (USPTO 11957739).
In: Cancer Vaccine Week, 2024-05-06, S. 130-130
serialPeriodical
Zugriff:
The Dana-Farber Cancer Institute Inc. has been granted a patent for compositions and methods to treat cancer, specifically diffuse gastric cancer (DGC). The patent focuses on using RHOA dominant negative forms to target the hyperproliferation of cancer cells with reduced or absent CDH1 expression, which is common in DGC. The invention involves administering a nucleic acid or polypeptide agent to patients with reduced CDH1 levels, and it can be combined with immunotherapy and/or cancer therapy. This research aims to identify new therapeutic targets for DGC and other epithelial/mesenchymal transition (EMT) cancers. [Extracted from the article]
Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Compositions and methods for treating cancer using RHOA dominant negative forms (USPTO 11957739).
|
---|---|
Zeitschrift: | Cancer Vaccine Week, 2024-05-06, S. 130-130 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6810 (print) |
Schlagwort: |
|
Sonstiges: |
|